Mihai Puia-Dumitrescu

Dr. Mihai Puia-Dumitrescu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
MPMihai Puia-Dumitrescu
Mihai Puia-Dumitrescu
BCBryan A. Comstock
Bryan A. Comstock
SLSijia Li
Sijia Li
PHPatrick J. Heagerty
Patrick J. Heagerty
KPKrystle M. Perez
Krystle M. Perez
VMVictor McKay
Victor McKay
The use of analgesia and/or sedation for the smallest premature infants with the most severe illness is at the discretion of the medical team, and the overall treatment goals are to mitigate pain, agitation, and discomfort. The American Academy of Pediatrics (AAP) recognizes that neonates at greatest risk of neurodevelopmental impairment as a result of preterm birth are also those most likely to be exposed to the greatest number of painful stimuli in the neonatal intensive care unit (NICU).1 The management of discomfort and agitation remains an integral part of the care for infants in the NICU, as acute and chronic pain result in heightened stress, hyperalgesia-associated reductions in white matter and corticospinal tract fractional anisotropy, and long-term behavioral changes.2-6 Thus, the AAP recommends pharmacologic and nonpharmacologic therapies for the prevention of pain associated with routine minor procedures as well as measures for minimizing pain associated with surgery and other major procedures.1,7 This recommendation is in stark contrast to prior practice, when infants received no analgesia during surgical procedures until the 1980s.8,9 Routine administration of opioids and benzodiazepines in extremely preterm (EP) infants is not recommended due to concerns regarding safety, efficacy, and potential long-term consequences.1,7

9 December 2021 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
KWKristin E. D. Weimer
Kristin E. D. Weimer
PSP. Brian Smith
P. Brian Smith
MPMihai Puia-Dumitrescu
Mihai Puia-Dumitrescu
SASamia Aleem
Samia Aleem

11 March 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
MPMihai Puia-Dumitrescu
Mihai Puia-Dumitrescu
TWThomas R. Wood
Thomas R. Wood
BCBryan A. Comstock
Bryan A. Comstock
JLJanessa B. Law
Janessa B. Law
KGKendell German
Kendell German
VMVictor McKay
Victor McKay
Bronchopulmonary dysplasia (BPD) is a common complication of prematurity, affecting 20% to 75% of infants born before gestational age (GA) 29 weeks.1-3 BPD is associated with delayed brain maturation and diffuse white matter anomalies that are associated with increased risk of neurodevelopmental impairment.4-6 Postnatal corticosteroids have been used to prevent and treat BPD for more than 50 years in multiple trials involving thousands of infants.7-9 Dexamethasone, a long-acting glucocorticoid agonist, is 1 of the top 20 medications used in extremely preterm infants,10,11 primarily to prevent or treat developing BPD. Multiple small trials and meta-analyses have demonstrated that short courses of low-dose dexamethasone may be useful for earlier weaning and extubation of infants undergoing mechanical ventilation at highest risk of BPD.8,9,12 However, the administration of dexamethasone to prevent BPD, especially in the first week of life, has been associated with increased risk for adverse effects, including cognitive, speech, and learning impairments, as well as cerebral palsy (CP).13-25 Routine dexamethasone therapy in the first week of life is not recommended.26-28 Currently, most clinicians prescribe low-dose, late-initiated dexamethasone29 of shorter duration than what was previously used28,30 to maximize benefits and minimize potential risks. Prednisolone and methylprednisolone are synthetic glucocorticoids with similar potency that are used interchangeably in practice to prevent or treat BPD. Their effectiveness has only been evaluated retrospectively.31,32

3 October 2019 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MPMihai Puia-Dumitrescu
Mihai Puia-Dumitrescu
DTDavid T. Tanaka
David T. Tanaka
TSTracy G. Spears
Tracy G. Spears
CDCecil J. Daniel
Cecil J. Daniel
KKKaran R. Kumar
Karan R. Kumar
PSP. Brian Smith
P. Brian Smith

3 August 2022 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
AMAhmed Moussa
Ahmed Moussa
TSTaylor Sawyer
Taylor Sawyer
MPMihai Puia-Dumitrescu
Mihai Puia-Dumitrescu
EFElizabeth E. Foglia
Elizabeth E. Foglia
AAAnne Ades
Anne Ades
NINational Emergency Airway Registry for Neonates (NEARNEOS) investigators
National Emergency Airway Registry for Neonates (NEARNEOS) investigators

11 September 2018 in Journal of Perinatology
Verified
Journal Article
Open access
PDF file
KGKeyaria D. Gray
Keyaria D. Gray
KDKathryn Dudash
Kathryn Dudash
CECarla Escobar
Carla Escobar
CFColman Freel
Colman Freel
THTylah Harrison
Tylah Harrison
OCon behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee
on behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee
Diazoxide is used to treat infants with persistent hypoglycemia, but the prevalence of its use and adverse effects are not well described. We report demographic and clinical characteristics of infants treated with diazoxide in neonatal intensive care units (NICUs). Retrospective cohort study of infants 24–41 weeks’ gestation admitted to 392 NICUs from 1997–2016, comparing characteristics between hypoglycemic infants exposed/not exposed to diazoxide. For diazoxide courses > 1 day, we report percentages of infants starting diuretics and/or developing new ventilator/oxygen requirement during therapy. Among 1,249,466 infants, 185,832 had hypoglycemia; 1066/185,832 (0.57%) received diazoxide. Diazoxide use increased over time (P = 0.001). Infants receiving diazoxide varied from 0–14.9% among centers. New diuretic courses were associated with 91/664 (14%), and new oxygen or ventilator requirement during therapy was associated with 64/556 (12%) and 34/647 (5%), respectively. Diazoxide use in NICU settings has increased over time. Infants receiving diazoxide commonly received diuretics.